A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma

Trial Profile

A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Dasatinib (Primary) ; Erlotinib (Primary) ; Gemcitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Sep 2012 New source identified and integrated (Vanderbilt-Ingram Cancer Center; VICCGI1173).
    • 14 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top